Influential Clinical Trials Arena Highlights Angiex’s AGX101 First-Patient Milestone
"The first-in-human open-label Phase I trial aims to evaluate the safety and pharmacokinetics of AGX101."
Angiex’s progress with AGX101 reached a wide audience through Clinical Trials Arena, a leading publication within the GlobalData portfolio known for its authoritative reporting on clinical trial developments. The article focused on Angiex’s recent milestone of dosing the first patient in the Phase 1 trial for AGX101, a novel TM4SF1-directed antibody-drug conjugate (ADC) that targets solid tumors by disrupting their blood supply. This first-in-human study is a significant step forward in exploring AGX101’s potential to address aggressive cancers.
The coverage by Clinical Trials Arena underscores the importance of AGX101 in the oncology landscape and highlights Angiex’s role as an emerging leader in next-generation cancer therapeutics.